Related Experiment Video
Updated: Jul 25, 2025
08:56
Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis
Published on: February 10, 2015
52.4K
Current Therapies for Cholestatic Diseases
Nahum Méndez-Sánchez1,2, Carlos E Coronel-Castillo3, Ana L Ordoñez-Vázquez1
1Unit Liver Research, Medica Sur Clinic & Foundation, Puente de Piedra 150, Toriello Guerra, Tlalpan, Mexico City 14050, Mexico.
Biomedicines
|June 28, 2023
Summary
Cholestasis, a decrease in bile flow, leads to severe liver diseases and complications. Understanding treatment options for these cholangiopathies is crucial for patient outcomes and quality of life.
Area of Science:
- Hepatology
- Gastroenterology
- Internal Medicine
Background:
- Cholestasis involves reduced bile flow, impacting intrahepatic and extrahepatic biliary trees.
- Progressive cholestatic liver diseases cause cirrhosis, liver failure, and other severe complications.
- These conditions significantly increase mortality, reduce quality of life, and impose economic burdens.
Purpose of the Study:
- To review the pathophysiology of cholangiopathies.
- To provide clinicians with an overview of current therapeutic options and their molecular targets.
- To summarize the safety and efficacy of cholangiopathy treatments based on existing evidence.
Main Methods:
- Literature review of existing evidence on cholangiopathies.
- Analysis of therapeutic options and their molecular targets.
- Synthesis of data on treatment safety and efficacy.
Main Results:
- Cholangiopathies encompass a range of progressive liver diseases affecting the biliary tree.
- Complications include cirrhosis, liver failure, malignancies, bone disease, and nutritional deficiencies.
- Effective management requires understanding pathophysiology and targeted therapies.
Conclusions:
- Clinicians need a comprehensive understanding of cholestatic liver disease treatments.
- Reviewing pathophysiology and therapeutic targets is essential for managing cholangiopathies.
- Evidence-based overview of treatment safety and efficacy aids clinical decision-making.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
706
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
706
01:29Chronic Pancreatitis II: Collaborative Care
116
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
116
01:29Inflammatory Bowel Disease IV: Pharmacological Management
155
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
155
01:17Hepatic Drug Excretion: Enterohepatic Cycling
1.6K
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
1.6K
01:26Diseases of the Liver and Gallbladder
674
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
674
01:29Drugs for Treatment of Ulcerative Colitis in IBD
179
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
179